Navigation Links
Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
Date:3/16/2009

AURORA, Ontario, March 16 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

The clinical study was designed, as mandated by regulatory authorities, to gather data on the absorption and elimination profile of Topical Interferon Alpha-2b in patients with low-grade cervical lesions, in addition to further data on its safety and efficacy. Depending on the data generated in the study, it is expected that interim results, which Helix anticipates will be received during its fiscal fourth quarter 2009, will allow the company to proceed with its planned regulatory filings in the U.S. and Europe respectively for its future Phase IIb and Phase III pivotal efficacy trials for this indication.

"This clinical study will build upon our previous clinical findings and increase our understanding of the drug's pharmacokinetic profile in patients with low-grade cervical lesions," said John Docherty, president of Helix BioPharma. "Receiving the necessary approvals to commence this study is a significant step as we continue to advance the clinical development of Topical Interferon Alpha-2b for this important therapeutic indication."

About the Clinical Study

The primary objective of the clinical study is to determine the multiple-dose pharmacokinetic profile of Topical Interferon Alpha-2b following intravaginal application every other day of a total of 14 doses of the cream. Following the pharmacokinetic portion of the trial, assessment of efficacy and safety parameters will continue until 35 doses of the cream have been applied. As such, the clinical study is designed to also provide support for the dosing regimen intended to be applied in the future to U.S. Phase IIb and European Phase III p
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...November 24 Shire plc (L...opharmaceutical company, today,announced that it h...y for,velaglucerase alfa, the company,s enzyme rep...of Type 1 Gaucher disease. This is the third marke...een submitted, with previous,submissions in the Un...
(Date:11/24/2009)...Y, Calif., Nov. 24 Genom...hat Randy Scott, Genomic Health,s Executive Chairm...Health Care Conference in New York City on Tuesday...ess the live and subsequently archived webcast of ...tion of Genomic Health,s website at http://invest...
(Date:11/24/2009)... Program Connects Customers with Partners Validate...A Genotek Products , Otta... a leading provider of products for biological sam...ay announced its new global partner program. The p...otek,s partner community and is designed to help p...
(Date:11/24/2009)...Nov. 24 Cell Therapeutic...ll present at the 21st Annual Piper Jaffray Health...mber 1-2, 2009, at the New York Palace Hotel. ,...00 a.m. Eastern Time in Holmes 1 (4th Floor). A li...ilable at www.celltherapeutics.com , and it will ...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...oved by the Fda For Hypotrichosis of,Eyelashes , ... approved LATISSE(TM),(bimatoprost ophthalmic solu... of the eyelashes. Eyelash hypotrichosis is anothe...es. LATISSE(TM) is the first and only,FDA-approved...nence as,measured by increases in length, thicknes...
... Southern California (USC) have, for the first tim...) cells from rats. This breakthrough finding will ...mal models for the study of a range of human disea.... 26 issue of the journal Cell . , "This is a m...know that rats are much more closely related to hu...
...stem against deadly bacteria. However, how the ste... body is not yet known. To date, B. Pseudomallei,... to elude medics. It can remain hidden in the huma...e immune system. The bacteria can suddenly become ...g in the patient dying from blood poisoning. AMC p...
Other Biology Technology:MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) -- 2MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) -- 3USC researchers derive first embryonic stem cells from rats 2USC researchers derive first embryonic stem cells from rats 3
(Date:11/24/2009)...d flabby arteries from collapsing have been true l... no longer needed -- once the arteries are strengt...s had no choice but to leave them in place. , Pr...rtment of Biomedical Engineering has developed a n...s where they,re needed, then dissolves. , "Our n...
(Date:11/24/2009)...is a matter of debate. A high-profile study a few ...t of their carbon from trees and leaves, evidence ...aquatic ecosystems. , But new research from the ...to be true. Algae provide a much richer diet for f...published this week in the Proceedings of the Nat...
(Date:11/23/2009)...er 23, 2009 Applied mathematicians dissected the ... ), a characteristic long leaf with a saddle-like ...e edges. The simple cause of the lily,s fan-like s...ng differential growthwas revealed by using an equ... Haiyi Liang, a postdoctoral student at Harvard,s...
Breaking Biology News(10 mins):A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3The cause behind the characteristic shape of a long leaf revealed 2Lexington International LLC Receives 2009 U S Presidents E Award Recognizing its Export Achievements 6381 1Lexington International LLC Receives 2009 U S Presidents E Award Recognizing its Export Achievements 6381 2Lexington International LLC Receives 2009 U S Presidents E Award Recognizing its Export Achievements 6381 3Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction Positive BPH Results 6378 1Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction Positive BPH Results 6378 2Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction Positive BPH Results 6378 3Drug for erectile dysfunction improves heart function in young heart disease patients 61624 1
...d gene therapy in two separate studies to renew br...and rats with a drug-induced form of Parkinson,s d...ientific publications Brain and The Journal of Neu...alt Parkinson,s disease at its onset and another s... occur when treating the disease in its later stag...
...y in St. Louis has proposed that evolution is the ...ment rather than physical processes, such as plate...iversity assistant professor of geomicrobiology in...in Arts & Sciences, studying Cyanobacteria ?ba...o produce oxygen and biomass ?has concluded that t...
...arolinska Institutet announced today that they hav...prove healthcare by accelerating the translation o...gnosis, prognosis, and treatment. , During the ne...s and measurement of gene expression in patients w...hritis, asthma and dyslexia. These diseases affect...
Other Biology News:Gene therapy for Parkinson's disease moves forward in animals 2Gene therapy for Parkinson's disease moves forward in animals 3Gene therapy for Parkinson's disease moves forward in animals 4Family trees of ancient bacteria reveal evolutionary moves 2Family trees of ancient bacteria reveal evolutionary moves 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3
Mouse Anti-Human Troponin I Monoclonal Antibody, Unconjugated, Clone 22B11 from Santa Cruz Biotechnology, Inc.
... freezers , Ultima II Series ,Developed ...represents the finest, most enhanced ultra-low fre...ood bank configurations, each Ultima II freezer in...system with built-in voltage boost and surge suppr...
Perfusion Pressure Kit - 8 channel from AutoMate Scientific, Inc
BspT107 I (HgiC I, Ban I) from Takara Mirus Bio
Biology Products: